Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (Nasdaq: STRO) is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) and other protein therapeutics for cancer. Its proprietary XpressCF® cell-free protein synthesis platform and XpressCF+® site-specific conjugation platform support the design and development of… From the company’s description.
Over the twelve months to Jun 30, 2026, Sutro Biopharma, Inc. reported revenue of $45.70M, down 56.3% from a year earlier, and a net loss of $180.64M. Its operating margin was −319.6%, and operations used $145.17M in cash. In fiscal 2025, it reported revenue of $102.48M, up 65.2% from fiscal 2024, and a net loss of $191.09M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sutro Biopharma, Inc. does
In the company’s own words
Sutro Biopharma, Inc. (Nasdaq: STRO) is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) and other protein therapeutics for cancer. Its proprietary XpressCF® cell-free protein synthesis platform and XpressCF+® site-specific conjugation platform support the design and development of homogeneous ADCs, immunostimulatory ADCs, bispecific ADCs and dual-payload ADCs. Its lead clinical candidate, STRO-004, is a tissue-factor-targeting ADC in a Phase 1 trial for advanced solid tumors; preclinical candidates include STRO-006, an integrin alpha v beta 6-targeting ADC, and STRO-227, a PTK7-targeting dual-payload ADC. The company also works with pharmaceutical and biotechnology partners on oncology therapeutics, and has granted Vaxcyte rights to use its technology for infectious-disease vaccines. Active collaborations include an immunostimulatory ADC program with Astellas. Sutro’s business centers on its therapeutic pipeline and platform-based collaborations rather than commercialized medicines. Its website is www.sutrobio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1382101
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sutro Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sutro Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sutro Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sutro Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sutro Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”